LMR Partners’s Immunic IMUX Stock Holding History

LMR Partners’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,000	Closed	-$35K	–	1259
2022 Q2	$35K	Buy	+1,000	New	+$64.1K	﹤0.01%	1190
2017 Q3	–	Sell	-341	Closed	-$396K	–	425
2017 Q2	$396K	Buy	+341	New	+$455K	0.02%	436

Other funds holding IMUX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

LMR Partners's IMUX Position: Q3 2022 in Review

LMR Partners sold out of Immunic (IMUX) in Q3 2022, closing a stake of 1,000 shares — an estimated $35K sold.

LMR Partners first reported a position in IMUX in Q2 2017 and held it in 2 quarters. The position peaked at $396K in Q2 2017. 65 funds tracked by Wall St. Rank hold IMUX as of Q3 2022.

LMR Partners reported no remaining Immunic position as of Q3 2022 after selling out during the quarter.
LMR Partners sold 1,000 Immunic shares in Q3 2022, an estimated $35K.
LMR Partners first reported a position in Immunic in Q2 2017 and held it in 2 quarters.
LMR Partners's Immunic position peaked at $396K in Q2 2017.
65 funds tracked by Wall St. Rank held Immunic as of Q3 2022.

Based on LMR Partners's 13F filing for Q3 2022, filed 14 Nov 2022.